Details

Autor(en) / Beteiligte

• Lydia Scarfò
• Georgios Karakatsoulis
• Dimitra Chamou
• Jana Kotaskova
• Christos Demosthenous
• Lukas Smolej
• Stephen Mulligan
• Salem Al-Shemari
• Thérèse Aurran-Schleinitz
• Francesca Bacchiarri
• Mar Bellido
• Fontanet Bijou
• Anne Calleja
• Angeles Medina
• Mehreen Ali Khan
• Ramona Cassin
• Sofia Chatzileontiadou
• Rosa Collado
• Amy Christian
• Zadie Davis
• David Donaldson
• Barbara Dreta
• Maria Efstathopoulou
• Shaimaa El-Ashwah
• Alberto Fresa
• Sara Galimberti
• Andrea Galitzia
• Rocío García-Serra
• Eva Gimeno
• Isabel González-Gascón-y-Marín
• Romain Guieze
• Ritu Gupta
• Sean Harrop
• Eleftheria Hatzimichael
• Luca Inchiappa
• Ozren Jaksic
• Susanne Janssen
• Volkan Karakus
• Arnon P. Kater
• Bonnie Kho
• Maria Kislova
• Ioannis Kotsianidis
• Robert J. Kreitman
• Jorge Labrador
• Deepesh Lad
• Mark-David Levin
• Ilana Levy
• Thomas Longval
• Alberto Lopez-Garcia
• Juan Marquet
• Lucia Martin-Rodríguez
• Marc Maynadié
• Carlota Mayor-Bastida
• Ivana Milosevic
• Fatima Miras
• Roberta Murru
• Almudena Navarro-Bailón
• Jacopo Olivieri
• Irina Panovska-Stavridis
• Zuzana Kubova
• Punyarat Phumphukhieo
• Anna Puiggros
• Lata Rani
• Gianluigi Reda
• Gian Matteo Rigolin
• Rosa Ruchlemer
• Marcos Daniel de Deus Santos
• Mattia Schipani
• Annett Schiwitza
• Dina Sameh Abdelrahman Soliman
• Martin Spacek
• Tamar Tadmor
• Eric Tse
• Theodoros Vassilakopoulos
• Candida Vitale
• Julia von Tresckow
• George Vrachiolias
• Vojin Vukovic
• Zhenshu Xu
• Lucrecia Yañez
• Mohamed Yassin
• Jana Zuchnicka
• Bella Biderman
• Mark Catherwood
• Rainer Claus
• Marta Coscia
• Blanca Espinet
• Gianluca Gaidano
• Olga B. Kalashnikova
• Luca Laurenti
• Eugene Nikitin
• Gerassimos A. Pangalis
• Panagiotis Panagiotidis
• Viola Maria Popov
• Sarka Pospisilova
• Paolo Sportoletti
• Constantine Tam
• Livio Trentin
• Michael Doubek
• Paolo Ghia

Titel

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYResearch in context

Ist Teil von

• EClinicalMedicine, 2023-11, Vol.65, p.102307

Ort / Verlag

Elsevier

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work. Methods: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022. Findings: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79–4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49–2.11; p < 0.001/OR = 1.89; 95% CI = 1.6–2.24; p < 0.001).CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36–2.41; p < 0.001/OR = 2.11; 95% CI = 1.12–3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08–0.33; p < 0.001).Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001). Interpretation: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS. Funding: AbbVie, and EU/EFPIA Innovative Medicines Initiative Joint Undertaking HARMONY grant n° 116026.